Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Part 3 of a three part study-- A Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection

Next Previous
Search
Trial Profile

Part 3 of a three part study-- A Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imdusiran (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arbutus Biopharma

    • Most Recent Events

    • 14 Nov 2023 Results of characterization of AB-729 HBV target site variants identified from the HBVdb database as well as from sequence profiling of the AB-729 target site at baseline in chronic hepatitis B (CHB) , presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 18 Apr 2023 According to an Arbutus Biopharma media release, abstract of this study has been accepted as late-breaker oral presentations at the Global Hepatitis Summit 2023.
    • 02 Mar 2023 According to an Arbutus Biopharma media release, in the first half of 2023, company anticipate announcing additional off-treatment data from those patients this trial, who have discontinued both AB-729 and nucleos(t)ide analogue (NA) therapy. Recently, one of the patients has met the protocol-defined HBV DNA criteria to restart their NA therapy and continuing to follow the seven patients who remain off-treatment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top